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Background and Objectives: 
Diabetes mellitus and Non-Alcoholic Fatty Liver Disease (NAFLD) are two highly 
prevalent and related diseases. Research have shown that they can affect the 
expression and activity of enzymes integral in the clearance of xenobiotics. Such 
enzymes include the Cytochrome P-450 isoforms 2C8 and 2C9. Our objective is to study 
the effect of these diseases on CYP2C8 and CYP2C9 using in vitro tools. 
Methods: 
A bank of donated livers was utilized for in vitro studies. Hepatic microsomal 
incubations of S-warfarin, a (CYP2C9) probe substrate, were performed to measure 
CYP2C9 activity by product formation and S-warfarin’s intrinsic clearance by in vitro half-
life approach.  Additionally, previously acquired data in our lab on mRNA and protein 
levels of CYP2C8 and CYP2C9 have been analyzed and compared among diabetic and 
NAFLD groups. 
Results and Conclusions: 
Analysis of CYP2C8 mRNA and protein expression in addition to CYP2C9 mRNA 
expression, activity, and warfarin’s intrinsic clearance showed no significant alteration 
by NAFLD nor diabetes. CYP2C9 protein expression significantly varied between 
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 Pathological conditions can produce changes in the expression and activity of 
drug metabolizing enzymes (DMEs) causing altered pharmacokinetic (PK) profiles of 
their substrate drugs (Sane & Sinz, 2017). If an alteration is clinically significant, 
individualized pharmacotherapy for the specific patient population is needed to ensure 
adequate treatment and avoid adverse drug reactions.  Therefore, it is crucial to 
perform additional studies on DME expression and activity in different disease 
populations. 
1.1. Phases of Metabolism 
 Hepatic metabolism is broadly classified into two phases which act to increase a 
chemical’s hydrophilicity facilitating its excretion (Cederbaum, 2015). Phase I involves 
oxidation, reduction, and hydrolysis reactions. Multiple enzyme families catalyze this 
phase. The most notable of which is the cytochrome P450 monooxygenation family 
(CYP). CYPs oxidize substrates by introducing one oxygen atom and utilizing 
nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor for the reaction. 
Alternatively, phase II is a conjugation phase where polar endogenous cofactors are 
conjugated with the substrate. An example of a phase II catalyzer is the uridine 5'-
diphospho-glucuronosyltransferase family (UGT) that conjugate their substrates with 
glucuronic acid. Endogenous and exogenous chemicals do not necessarily undergo both 




would undergo both. Compounds hydrophilic enough to be excreted from the body 
unchanged do not undergo metabolism at all. 
1.2. CYP2C Subfamily 
 CYP2C is a subfamily of cytochrome P450 enzymes that has four isoforms in 
humans: CYP2C8, CYP2C9, CYP2C18, and CYP2C19 (Goldstein, 2001). Members of this 
subfamily are involved in the metabolism of endogenous compounds such as 
arachidonic acid in addition to xenobiotics. 
 Arachidonic acid is an endogenous fatty acid that is found in cellular membranes. 
It is metabolized to active products via three enzymatic systems one of which is the CYP 
system.  Studies by Rifkind, Lee, Chang, & Waxman (1995) have shown that both CYP2C8 
and CYP2C9 play an important role in arachidonic acid metabolism through the CYP 
epoxygenase pathway. The resulting metabolites, called epoxyeicosatrienoic acids 
(EETs), are involved in numerous biological activities such as vascular smooth muscle 
homeostasis, endothelial calcium signaling, and regulation of cardiac muscles’ ion 
channels (Spector, Fang, Snyder, & Weintraub, 2004). 
 CYP2C8 is a CYP isoform that is involved in the hepatic clearance of nearly 5% of 
prescribed medications (Naraharisetti et al., 2010).  The importance of this enzyme in 
drug development studies has not been recognized until the recent years (Backman, 
Filppula, Niemi, & Neuvonen, 2016).  As a result, research on CYP2C8 phenotypes at 
Messenger Ribonucleic Acid (mRNA) level, protein expression, and enzyme activity, with 




several antidiabetic drugs, it is important to study its expression and activity in this 
population. For example, CYP2C8 is the primary metabolizing enzyme for the 
thiazolidinedione insulin sensitizers, rosiglitazone (Baldwin, Clarke, & Chenery, 1999) 
and pioglitazone (Jaakkola, Laitila, Neuvonen, & Backman, 2006), and the meglitinide 
insulin secretagogue, repaglinide (Bidstrup, Bjornsdottir, Sidelmann, Thomsen, & 
Hansen, 2003). In addition, CYP2C8 is involved in the metabolism of other antidiabetics 
as a minor pathway. 
 CYP2C9 is another enzyme that has an essential role in xenobiotic metabolism.  It 
is the second most abundant CYP enzyme in the human liver, after CYP3A4, and is 
involved in phase I biotransformation of about 1/5 of all drugs.  One of the widely 
prescribed CYP2C9 substrates is warfarin (Van Booven et al., 2010). 
1.3. Effect of Diabetes Mellitus 
 According to the World Health Organization (WHO), the worldwide prevalence of 
diabetes has substantially increased to 8.5% of the population in 2014 (World Health 
Organization, 2017).  A considerable number of patients with type 2 diabetes mellitus 
(T2DM) may have compromised hepatic function and other metabolic disorders.  
Although multiple research groups have studied the effects of T2DM on drug 
metabolism, the knowledge in this field is still limited to certain enzymes. For example, 
the in vivo activity of CYP2E1 is increased in obese T2DM patients using chlorzoxazone 
as a probe substrate (Lucas et al., 1998; Wang et al., 2003). CYP3A4 appears to be 




Yan, & Akhlaghi, 2011; Hu et al., 2014; Patoine et al., 2014). This conflict could be a 
result of species differences, variations in disease length, level of disease control and 
other factors. 
To the best of our knowledge, there are no studies on the expression and activity 
of CYP2C8 and CYP2C9 in diabetic populations. However, there are studies showing 
altered pharmacokinetic profiles of clinically used drugs in diabetic states. Upon 
conducting a comprehensive review on PK in diabetes, thirty-five reports were found in 
the literature between January 1st, 2012 and September 4th, 2018 (Table 1). Reports 
prior to 2012 have been reviewed elsewhere (Dostalek, Akhlaghi, & Puzanovova, 2012). 
Several studies included drugs that are well known CYP2C8 or CYP2C9 substrates. For 
example, the non-steroidal anti-inflammatory drug (NSAID) diclofenac had altered PK 
parameters in diabetic animals as compared to non-diabetic controls (Ahmad, Iqbal, & 
Murtaza, 2012; Y. Li, Wei, Zhang, Wang, & Wu, 2012). An animal study published in 2016 
by Zhou and colleagues, comparing diabetic to non-diabetic rats, reported five different 
drugs including glibenclamide. Glibenclamide (metabolized by CYP2C9 and CYP3A4) had 
alterations in all PK parameters measured: The area under the concentration-time curve 
until the last quantifiable value (AUC), clearance (CL), volume of distribution (Vd), and 
elimination half-life (t ½). Glibenclamide has also been reported to have different PK in 
diabetic rats by Y. Li, Wei, Zhang, Wang, and Wu (2012). The study included two routes 
of administration (oral and intravenous) and the PK differed under diabetic conditions 
for both routes. It is important to note however that not all substrates of CYP2C8 and 




instance, the PK of rosiglitazone (Zhou et al., 2016) and losartan (Li et al., 2017) did not 
substantially differ between the groups. Involvement of alternative metabolic pathways 








    Table 1. Influence of Diabetes Mellitus on Pharmacokinetics (Studies reported between 1/1/2012 – 9/4/2018) 
Drug Species Major DMEs PK parameters Non-diabetic Diabetic p-value Reference 




t ½ (h) 
CL (L/h) 
Vd (L/kg) 




(Mean ± SD) 
0.55 ± 0.10 
1.31 ± 0.24 
3.52 ± 0.54 
1.70 ± 0.49 
40.35 ± 7.18 
67.04 ± 9.11 
0.083 ± 0.00 
0.89 ± 0.13 
(Mean ± SD) 
0.43 ± 0.15 
1.76 ± 0.49 
4.99 ± 0.89 
3.83 ± 0.87 
23.11 ± 3.98 
50.96 ± 6.32 
0.083 ± 0.00 



















t ½ (min) 
 
(Mean ± SEM) 
2.0 ± 1.1 
491.1 ± 91.3 
158 ± 71 
(Mean ± SEM) 
4.9 ± 0.9 
1418.0 ± 341.8 





Li et al. 
2017 











CL (mL/min per kg) 
Vdss (L/kg) 
t ½ (h) 
(Mean ± SD) 
5.4 ± 0.6 
5.8 ± 0.7 
6.5 ± 0.8 
 
3.4 ± 0.3 
6.2 ± 0.6 
(Mean ± SD) 
8.6 ± 1.6 
9.7 ± 1.8 
4.0 ± 0.8 
 
2.4 ± 0.3 









Zhou et al. 
2016 











t ½ (h) 
AUC (ng x h/mL) 
AUCinf (ng x h/mL) 
 
(Mean ± SD) 
1.82 ± 1.86 
1.39 ± 1.26 
2.05 ± 1.54 
4.95 ± 3.70 
6.33 ± 4.32 
 
(Mean ± SD) 
2.34 ± 2.29 
1.40 ± 0.79 
1.33 ± 0.81 
5.01 ± 4.11 

















































(ng/mL) after 0.5 





(ng/mL) after 3 



















































(Mean ± SD) 
299.90 ± 93.73 
61.76 ± 16.13 
11.5 ± 0 
(Mean ± SD) 
319.88 ± 129.01 
62.09 ± 10.51 
















(Mean ± SD) 
164080 ± 68990 
29330 ± 6410 
11.5 ± 0 
(Mean ± SD) 
921880 ± 267750 
131330 ± 41430 















t ½ (min) 
 
(Mean ± SEM) 
0.08 ± 0.03 
19.1 ± 7.8 
123 ± 30 
(Mean ± SEM) 
0.17 ± 0.10 
37.0 ± 23.3 





Li et al. 
2017 







C max (μg/ml) 
(Mean ± SEM) 
 
37.4 ± 0.21 
 1.67 ± 1.50 
(Mean ± SEM) 
 
49.95 ± 0.22 



























C max (μg/ml) 
Ka (1/h) 
MAT (1/h) 





t ½ (h) 
CL (ml/h/Kg) 
 
13.64 ± 0.38 
0.50 ± 2.48 
2.18 ± 1.27 
1.51 ± 1.52 
2.68 ± 1.45 
4.71 ± 0.63 
0.68 ± 1.8 
0.39 ± 3.11 
1.86 ± 1.74 
1.77 ± 1.09 
 
 
80.73 ± 0.16 
1.71 ± 1.97 
26.83 ± 0.31 
0.86 ± 2.49 
1.2 ± 2.07 
0.83 ± 2.49 
2.91 ± 1.15 
2.16 ± 0.995 
0.29 ± 2.95 
0.63 ± 3.69 
2.02 ± 1.38 
0.72 ± 2.02 
12.84 ± 0.41 
0.43 ± 1.96 
3.91 ± 0.52 
2.71 ± 0.62 
2.92 ± 1.65 
3.41 ± 0.85 
0.4 ± 2.56 
0.34 ± 5.07 
2.06 ± 1.98 
1.16 ± 1.51 
 
 
50.73 ± 0.19 
1.85 ± 1.38 
18.13 ± 0.42 
1.07 ± 4.46 
0.94 ± 4.92 
0.65 ± 5.92 
2.99 ± 1.41 
3.68 ± 0.72 
0.47 ± 1.71 
0.39 ± 4.16 
2.07 ± 1.68 

























Diclofenac Rat CYP2C9 
ortholog 
 
t ½ (min) 
CL (x 10^3, 
L/min/kg) 
AUC (mg x min/L) 
 
(Mean ± SD) 
170.08 ± 24.73 
11.29 ± 1.08 
 
684.60 ± 63.47 
(Mean ± SD) 
288.93 ± 46.33 
4.67 ± 0.58 
 






Li et al. 
2012 







(Mean ± SD) 
 
225 ± 44 
 
(Mean ± SD) 
 




















C max (μg/ml) 
Tmax (min) 
t ½ (min) 
 
173 ± 24 
23 ± 4 
650 ± 130 
 
 
18.5 ± 4.3 
 
0.0760 ± 0.03 
145 ± 101 
156 ± 96 
 
132 ± 43 
25 ± 3 
290 ± 130 
 
 
25.2 ± 15.7 
 
0.101 ± 0.06 
138 ± 95 







































(Mean ± SD) 














(Mean ± SD) 

















dhe et al. 
2017 
Ethambutol Human Mainly 
excreted 
unchanged 









30 days (μg/mL) 
 
(Mean ± SEM) 
 
2.81 ± 0.30 
 
 
3.6 ± 0.3 
(Mean ± SEM) 
 
3.70 ± 0.64 
 
 






















CL (mL/min per kg) 
Vdss (L/kg) 
t ½ (h) 
(Mean ± SD) 
5.1 ± 1.5 
5.3 ± 1.6 
6.8 ± 1.6 
2.4 ± 0.2 
4.8 ± 0.8 
(Mean ± SD) 
10 ± 1.5 
24 ± 6.3 
1.5 ± 0.5 
3.6 ± 0.5 






















t ½ (min) 




(Mean ± SD) 
 
84.78 ± 15.96 
0.26 ± 0.03 
0.09 ± 0.01 
57.75 ± 18.93 
 
 
225.47 ± 25.34 
7.61 ± 1.53 
 
509.52 ± 56.14 
(Mean ± SD) 
 
255.43 ± 23.8 
0.91 ± 0.14 
0.02 ± 0.01 
321.24 ± 130.37 
 
 
560.90 ± 166.22 
2.67 ± 0.70 
 
























AUC (μg/mL h) 
AUCinf (μg/mL h) 




(Mean ± SD) 
29.4 ± 0.7 
2 
109.3 ± 3.3 
118.2 ± 3.5 
1.67 ± 0.1 
4.11 ± 0.1 
82.1 ± 1.4 
233.5 ± 7.5 
(Mean ± SD) 
68.0 ± 1.5 
2 
275.2 ± 6.2 
305.2 ± 8.9 
1.87 ± 0.1 
4.34 ± 0.1 
32.4 ± 1.1 




















AUC (μg/mL h) 
AUCinf (μg/mL h) 
t ½ (h) 
MRT (h) 
(Mean ± SD) 
18.7 ± 0.8 
4 
161.7 ± 4.4 
170.5 ± 6.7 
5.6 ± 1.0 
10.7 ± 0.9 
(Mean ± SD) 
21.4 ± 1.3 
4 
177.9 ± 9.7 
198.2 ± 14.5 
6.1 ± 0.7 
















Vd (mL)  
325.1 ± 12.5 
56.3 ± 5.6 
306.2 ± 12.3 




IgG Rat Metabolism 
by 
phagocytic 



















































30 days (μg/mL) 
(Mean ± SEM) 
 





2.9 ± 0.2 
 
(Mean ± SEM) 
 




































































Itopride Rat FMO  
Cmax (μg/mL) 
Tmax (h) 
(Mean ± SEM) 
2.72 ± 0.03 
2 ± 0 
(Mean ± SEM) 
3.92 ± 0.07 

















21.9 ± 0.118 
27.49 ± 0.808 
12.03 ± 1.11 
26.71 ± 0.18 
497.65 ± 3.09 
42.49 ± 11.1 
59.53 ± 41.7 
























(Mean ± SD) 
2.72 ± 2.45 
0.75 ± 0.47 
3.33 ± 0.47 
 
 
(Mean ± SD) 
2.93 ± 2.18 
0.63 ± 0.39 





























(Mean ± SD) 
2.29 ± 0.52 
3.17 ± 0.75 
0.12 ± 0.09 
11.67 ± 10.68 
1.78 ± 0.99 
20.67 ± 7.49 
23.86 ± 7.74 
37.12 ± 21.38 
7.19 ± 3.15 
(Mean ± SD) 
4.15 ± 1.79 
2.83 ± 1.60 
0.14 ± 0.06 
5.65 ± 1.99 
1.17 ± 0.45 
10.65 ± 5.95 
43.28 ± 16.58 
47.17 ± 14.87 





















t ½ (min) 
 
(Mean ± SEM) 
0.15 ± 0.13 
64.6 ± 115.1 
114 ± 51 
 
(Mean ± SEM) 
0.94 ± 1.12 
123.9 ± 109.0 







Li et al. 
2017 







CL (mL/min per kg) 
Vdss (L/kg) 
t ½ (h) 
(Mean ± SD) 
1.9 ± 0.4 
1.9 ± 0.4 
71 ± 16 
3.4 ± 2.3 
2.6 ± 3.6 
(Mean ± SD) 
1.5 ± 0.2 
1.5 ± 0.2 
90 ± 14 
3.7 ± 0.7 





































































































 (6.38, 11.24) 
 
0.09 
 (0.06, 0.13) 
 
35.38 
 (23.81, 87.46) 
 
5.29 





























 (0.12, 0.26) 
 
25.60 
 (15.95, 66.19) 
 
4.85 






























































































 (3.08, 7.13) 
 
0.16 
































































































































t ½ (min) 
(Mean ± SEM) 
0.30 ± 0.15 
36.7 ± 11.8 
88 ± 38 
 
(Mean ± SEM) 
0.26 ± 0.10 
47.9 ± 18.5 







Li et al. 
2017 
















































































































t ½ (min) 
 
(Mean ± SEM) 
0.6 ± 0.7 
36.2 ± 31.7 
70 ± 45 
(Mean ± SEM) 
3.1 ± 1.9 
314.5 ± 195.4 





Li et al. 
2017 
















C max (μg/ml) 
Tmax (min) 
t ½ (min) 
 
(Mean ± SD) 
 
475 ± 25 
 
115 ± 10 
11 ± 1 
670 ± 40 
 
 
17.2 ± 8.4 
 
0.04 ± 0.03 
261 ± 139 
214 ± 66 
(Mean ± SD) 
 
523 ± 78 
 
158 ± 46 
10 ± 2 
580 ± 22 
 
 
27.0 ± 6.9 
 
0.07 ± 0.03 
206 ± 118 















Lee et al. 
2012 







(Mean ± SD) 
0.34 ± 0.03  
(Mean ± SD) 













AUC (μg h/mL) 




(Mean ± SEM) 
5.55 ± 0.47 
4.00 ± 0.00 
42.42 ± 4.13 
3.62 ± 0.22 
0.192 ± 0.01 
5.58 ± 0.14 
 
(Mean ± SEM) 
5.91 ± 0.52 
4.00 ± 0.00 
51.19 ± 13.5 
3.86 ± 0.09 
0.180 ± 0.004 





























(ng/mL) after 0.5 





(ng/mL) after 3 




































































 [0.621, 0.877] 
 
5.33 
 [4.53, 6.27] 
 
5.97 
 [5.49, 6.49] 
 
3.29 








 [2.05, 4.08] 
 
geometric  






















































 [8.66, 12.0] 
 [1.57, 2.03] 
 
8.97 

























t ½ (h) 
median  




 [0.558, 1.65] 
 
Geometric 









 [4.09, 4.89] 
 
2.83 
 [2.63, 3.04] 
Median 




 [1.04, 2.44] 
 
Geometric 
 mean [95% CI] 
 
4.11 






 [4.72, 5.65] 
 
3.12 







































(Mean ± SEM) 
 





(Mean ± SEM) 
 























30 days (μg/mL) 
 
27.9 ± 1.6 23.4 ± 1.9 NS 
Remogliflozin 
etabonate 
Human Possibly CYP 
and UGT 




C max (ng/ml) 




















































AUC (μg · h/mL) 
AUCinf (μg · h/mL) 





(Mean ± SD) 
3.78 ± 0.53  
1 ± 0  
23.06 ± 3.18  
23.18 ± 3.14  
 
3.05 ± 0.50  
5.77 ± 0.40  
9.13 ± 1.73 
39.62 ± 6.31  
(Mean ± SD) 
7.4 ± 0.66  
1.16 ± 0.41  
41.39 ± 6.36  
42.39 ± 6.54  
 
3.91 ± 1.69  
6.21 ± 1.83  
4.58 ± 1.7  























30 days (μg/mL) 
(Mean ± SEM) 
 





5.4 ± 0.5 
(Mean ± SEM) 
 




























AUC (mg · h/L) 






t ½α (h) 
Vd (L/kg) 
ke (1/h) 





11.41 ± 3.8 
2.32 ± 1.4 
82.60 ± 35.5 
87.07 ± 39.9 





0.84 ± 0.31 
0.21 ± 0.1 
4.31 ± 1.7 
8.62 ± 3.9 
TB + T2DM patients 
 
12.10 ± 5.1 
2.98 ± 1.9 
97.52 ± 36.7 
107.73 ± 56.3 






0.63 ± 0.21 
0.19 ± 0.08 
3.97 ± 1.5 



































min per kg) 
Vdss (L/kg) 
t ½ (h) 
 
(Mean ± SD) 
40 ± 12 
40 ± 12 
1.2 ± 0.3 
 
0.3 ± 0.0 
2.9 ± 0.2 
 
(Mean ± SD) 
32 ± 7 
32 ± 7 
1.5 ± 0.3 
 
0.2 ± 0.0 



































Cao et al. 
2012 
Sunitinib Rabbit CYP3A4  
AUC (ng x h/mL) 
AUCinf (ng x h/mL) 
 
(Mean ± SD) 
2303.6 ± 1069.1 
2425.0 ± 1077.5 
 
(Mean ± SD) 
3785.8 ± 1282.5 




















23.2 ± 7.6 
12.1 ± 5.4 
418.2 ± 223.4 
92.1 ± 22.1 
7.2 ± 0.8 
23.3 ± 2.8 
31.6 ± 19.1 
5.7 ± 1.6 
242.3 ± 120.0 
149.2 ± 33.7 
8.8 ± 2.1 
















 mg dose) 
 
AUC (ng*hour/ 













































































mean ± SD or median 
(range) 
2.7 ± 1.1 
2.5 (2.0–3.0) 
8.9 ± 2.2 
28.7 ± 9.6 
11.4 ± 3.3 




mean ± SD or 
median (range) 
1.5 ± 0.5 
5.9 (1.2–8.0) 
9.1 ± 3.6 
18.5 ± 9.7 
15.0 ± 6.8 

































































































































































































































CL (mL/min per kg) 
Vdss (L/kg) 
t ½ (h) 
 
(Mean ± SD) 
0.6 ± 0.1 
0.6 ± 0.1 
63 ± 10 
1.6 ± 0.6 
2.0 ± 1.2 
 
(Mean ± SD) 
1.1 ± 0.4 
1.3 ± 0.6 
35 ± 15 
4.7 ± 3.2 
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2016 
 
 DMEs = Drug Metabolizing Enzymes, PK = Pharmacokinetic, T2DM = Type 2 Diabetes Mellitus, TB = Tuberculosis, ke = elimination rate constant, Ka = 
 absorption rate constant, t ½ = elimination half-life, t ½α = absorption half-life, AUC = area under the concentration-time curve until the last 
 quantifiable value, AUCinf = AUC extrapolated from time zero to infinity, CL = clearance, CL/F = total apparent clearance, CLR = renal clearance, CLNR = 
 non-renal clearance, Vd = volume of distribution, V/F = apparent volume of distribution, Vdss = volume of distribution at steady state, Vc = central 
 volume of distribution, Vp = peripheral volume of distribution, Cmax = maximum observed plasma concentration, Tmax = time to reach maximum 
 concentration (Cmax), MRT = mean residence time, MTT = mean transit time, MAT = mean absorption time, D = dose, DMIA = diabetes mellitus 
 induced by alloxan, DMIS = diabetes mellitus induced by streptozotocin, IV = intravenous, CI = confidence interval, CV = coefficient of variance, NS = 




1.4. Effect of Non-alcoholic Fatty Liver Disease 
 NAFLD is a health issue that has been on the rise globally.  It is defined as an 
abnormal fat accumulation in the liver without significant alcohol consumption or other 
secondary causes.  NAFLD is further sub-classified to non-alcoholic fatty liver (NAFL) 
where there is only simple steatosis and non-alcoholic steatohepatitis (NASH) where 
steatosis is accompanied by liver cell injury and inflammation and in some cases fibrosis 
(Chalasani et al., 2012). There are many inconsistent reports on NAFLD prevalence. This 
is mainly due to the different methods used for diagnosis. In a recent meta-analysis, the 
estimated global prevalence was approximately 25% when including patients diagnosed 
by imaging methods only (Younossi et al., 2016).  The effect of NAFLD on DMEs has 
become a topic of interest. As in the case of T2DM, the effect seems to differ for each 
CYP450 enzyme. A clinical study in a pediatric population reported no change in CYP2C9 
enzyme activity in the NASH group compared to the healthy group (H. Li et al., 2017). An 
in vitro study using human liver microsomes (HLM) from healthy and NAFLD adults 
showed a significant increase in CYP2C9 enzyme activity measured with two probe 
substrates, diclofenac and tolbutamide (Fisher et al., 2009). Concerning CYP2C8, the 
study by Fisher and his colleagues (2009) is the only study reporting this enzyme’s 
phenotypes in NAFLD. Their results showed no change in CYP2C8 enzyme activity and 
mRNA level with disease progression. However, there was a non-statistically significant 
decrease in protein level. We believe that these results are not conclusive. More 





1.5. Warfarin as a Probe Substrate 
 Warfarin is an anticoagulant that exerts its pharmacological action by interfering 
with the function of vitamin K as an essential component of the clotting cascade. The 
pharmacokinetics of warfarin has been extensively studied. Following oral 
administration, it is easily absorbed through the gastrointestinal tract and then highly 
bound to plasma proteins once in the main bloodstream which limits its distribution. 
Hepatic metabolism is the main route of clearance with little to no role of kidneys in 
excreting the parent compound (Park, 1988). The approved dosage form is a mixture of 
S- and R- enantiomers. These enantiomers have shown different potency and 
pharmacokinetic profiles (Choonara, Haynes, Cholerton, Breckenridge, & Park, 1986). S- 
warfarin is more potent as measured by the level of increase in prothrombin time (Park, 
1988). Regarding PK differences, S-warfarin is majorly metabolized by CYP2C9 to 7-
hydroxy warfarin while R-warfarin goes through multiple pathways and CYP2C9 plays a 
minor role in its biotransformation.  Findings from pharmacogenetic research suggest 
that CYP2C9 is the main CYP enzyme implicated in the clearance of warfarin and the 
inter-individual variability to this drug ("COUMADIN Prescribing information," 2011). The 
clinical relevance of S-warfarin coupled with its sensitivity to CYP2C9 alterations makes 






2.1 Chemicals and Supplies 
 S-warfarin, S-7-hydroxywarfarin, and S-7-hydroxywarfarin-d5 were obtained 
from Toronto Research Chemicals (North York, Ontario, Canada). Individual Human liver 
tissue samples and Xtreme pool of 200 human liver microsomes were purchased from 
Sekisui XenoTech (Kansas City, KS, USA).  Tetrasodium salt of reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) was purchased from EMD Millipore 
(Burlington, MA, USA). LC/MS grade acetonitrile and methanol were obtained from 
ThermoFisher Scientific (Waltham, MA, USA). All other solvents were of analytical grade. 
2.2 Liver Tissue Grading and Processing 
 Individual human liver tissue samples were commercially obtained from Sekisui 
XenoTech. Demographics and diabetic status of the liver donors were provided by the 
supplying company However, their identities were not known. Therefore, the research is 
exempt from review by The University of Rhode Island institutional review board (IRB) 
under exempt category # 4. Grading of liver tissues for NAFLD presence and severity was 
done by a histopathologist collaborating with our lab (Dr. Suzanne Delamonte, MD). 
Liver tissues were then categorized as: normal, NAFL, or NASH as described in detail by 




 Human liver microsomes were prepared in our lab by homogenization of the 
liver tissue samples using automated Omni Bead Ruptor 24 homogenizer (Omni 
International, Kennesaw, GA, USA). Homogenates were then differentially centrifuged 
using Eppendorf’s 5810R Centrifuge (Eppendorf, Hamburg, Germany) then Beckman 
Coulter's ultracentrifuge (Beckman Coulter, Brea, CA) to obtain microsome pellets that 
were resuspended in glycerol buffer and stored in - 80 Cᴼ for later use (Jamwal et al., 
2017). 
 To account for the effects of enzyme inducers and inhibitors potentially taken by 
liver donors prior to death, our lab recently completed a project to detect several 
commonly used drugs which possess CYP450 induction or inhibition properties in the 
liver bank (Barlock & Jamwal, 2018. Manuscript in preparation). Three CYP2C8 inducers, 
two CYP2C9 inducers, and eleven CYP2C9 inhibitors were detected. 
 Table 2 shows the donors’ demographics and the most frequently detected 
CYP2C8/2C9 inducers and inhibitors in the liver bank (n=106). CYP2C8’s and CYP2C9’s 
mRNA and protein levels were measured for all 106 livers in our lab using validated 
procedures (Jamwal et al., 2017). Table 3 shows the donor’s demographics and the most 
frequently detected CYP2C9 inducers and inhibitors in a subset of the liver bank that 
was included in measuring CYP2C9 activity (n=76). Limited sample quantities prevented 








    Table 2. Donors’ demographics and detected CYP2C8/2C9 inducers and inhibitors in all livers (n=106) 
 Non-diabetic/no NAFLD (n=21)    Diabetic only (n=21)    NAFLD only (n=32)    Diabetic + NAFLD (n=32) 
Age 




            
            49.43 ± 16.14                      48.62 ± 13.63                      52.31 ± 10.87                             53.28 ± 9.45 
 
                (21,73)                                  (21,78)                                   (33,76)                                       (38,74) 
Gender (%)         Females (42.9)                     Females (33.3)                      Females (50.0)                 Females (56.3) 
          Males (57.1)                        Males (66.7)                           Males (50.0)                     Males (43.8) 
Ethnicity (%)     Caucasians (81.0)                  Caucasians (76.2)                   Caucasians (90.6)          Caucasians (90.6)                                                                   
African Americans (19.0)    African Americans (19.0)    African Americans (3.1)    African Americans (3.1)                                                                                         
       Hispanics (0.0)                    Hispanics (4.8)                          Hispanics (6.3)                 Hispanics (6.3)                                                                        
BMI (%)       <30 (66.7)                                 <30 (52.4)                                <30 (50.0)                          <30 (34.4) 
       ≥30 (33.3)                                 ≥30 (47.6)                               ≥30 (50.0)                          ≥30 (65.6) 
CYP2C8 
Polymorphism (%) 
   *1/*1 (100.0)                            *1/*1 (81.0)                         *1/*1 (71.9)                         *1/*1 (81.3) 
   *1/*3 (0.0)                                *1/*3 (19.0)                          *1/*3 (28.1)                         *1/*3 (15.6) 
   *3/*3 (0.0)                                *3/*3 (0.0)                             *3/*3 (0.0)                          *3/*3 (3.1) 
CYP2C9 
Polymorphism (%) 
   *1/*1 (100.0)                            *1/*1 (81.0)                          *1/*1 (68.8)                        *1/*1 (81.3) 
   *1/*2 (0.0)                                *1/*2 (19.0)                          *1/*2 (31.3)                         *1/*2 (15.6) 
   *2/*2 (0.0)                                *2/*2 (0.0)                             *2/*2 (0.0)                           *2/*2 (3.1) 
Dexamethasone 
(CYP2C8 inducer) (%) 
  Present (19.0)                         Present (19.0)                        Present (25.0)                      Present (19.4) 

























   Present (38.1)                      Present (23.8)                     Present (31.3)                       Present (32.3) 
   Absent (61.9)                       Absent (76.2)                      Absent (68.8)                         Absent (67.7) 
Tetrahydrocannabinol 
(CYP2C9 inhibitor) (%) 
   Present (57.1)                      Present (57.1)                     Present (75.0)                       Present (80.6) 






  Table 3. Donor’s demographics and detected CYP2C9 inducers/inhibitors in livers included in CYP2C9 activity   
  measurements (n=76) 
 Non-diabetic/no NAFLD (n=16)   Diabetic only (n=16)    NAFLD only (n=25)    Diabetic + NAFLD (n=19) 
Age 
(mean ± SD) 
 
(minimum, maximum) 
             
  49.13 ± 16.42                              45.44 ± 12.88                      52.68 ± 11.8                          52.47 ± 8.87 
 
     (21,73)                                           (21,70)                                 (33,76)                                    (38,74) 
Gender (%)   Females (43.8)                          Females (31.3)                     Females (48.0)                      Females (68.4) 
   Males (56.3)                             Males (68.8)                          Males (52.0)                           Males (31.6) 
Ethnicity (%) Caucasians (75.0)                      Caucasians (75.0)               Caucasians (88.0)                 Caucasians (94.7)                                                                   
African Americans (25.0)    African Americans (18.8)   African Americans (4.0)   African Americans (5.3)                                                                                         
 Hispanics (0.0)                         Hispanics (6.3)                      Hispanics (8.0)                      Hispanics (0.0)                                                                        
BMI (%)   <30 (68.8)                                  <30 (50.0)                               <30 (48.0)                              <30 (31.6) 
   ≥30 (31.3)                                  ≥30 (50.0)                              ≥30 (52.0)                              ≥30 (68.4) 
CYP2C9 Polymorphism 
(%) 
 *1/*1 (100.0)                           *1/*1 (81.3)                          *1/*1 (76.0)                          *1/*1 (73.7) 
 *1/*2 (0.0)                               *1/*2 (18.8)                          *1/*2 (24.0)                          *1/*2 (21.1)    
 *2/*2 (0.0)                                *2/*2 (0.0)                             *2/*2 (0.0)                             *2/*2 (5.3) 
Phenytoin 
(CYP2C9 inducer) (%) 
Present (50.0)                         Present (31.3)                        Present (32.0)                      Present (26.3)  
Absent (50.0)                          Absent (68.8)                         Absent (68.0)                        Absent (73.7) 
Tetrahydrocannabinol 
(CYP2C9 inhibitor) (%) 
 Present (56.3)                        Present (56.3)                       Present (68.0)                       Present (84.2) 




2.3 Preliminary Experiments for CYP2C9 Activity Measurement 
 Detection system linearity was assessed by injecting a wide concentration range 
of S-warfarin (0.5 – 64 uM) and S-7OH-warfarin (0.25 – 64 uM) pure standards and 
plotting them against their peak areas as measured by LC-MS/MS. 
 Sekisui XenoTech Xtreme pool of 200 human liver microsomes was used to 
determine the optimal incubation settings prior to measurements in donor-specific liver 
microsomes. 
 Time and protein linearity experiments were performed to determine incubation 
times and microsomal protein concentrations where product formation is within the 
linear range. 
 In time linearity experiment, incubations were carried out in 100 mM Phosphate 
buffer containing 3 mM MgCl2 and 1 mM EDTA (pH 7.4). The incubation mixture 
consisted of 0.2 mg/mL HLM, 3.85 uM S-warfarin, and 1.3 mM NADPH. A water bath set 
at 37 ᴼC was used to simulate body temperature.  Aliquots were withdrawn from the 
incubation plate at 0, 20, 40, 60, 80, 100, 120, and 140 minutes and added to a 
quenching plate containing ice cold acetonitrile and internal standard (IS) (2 uM S-7-
hydroxywarfarin-d5) to stop the reaction. Afterwards, the samples were centrifuged at 
3200 g for 10 minutes and the resulting supernatants were injected into LC-MS/MS for 
metabolite quantification. Quantity of the metabolite S-7-hydroxywarfarin formed was 




 In protein linearity experiment, the same incubation mixture and settings were 
implemented except for HLM concentration where a range of (0.025 – 1 mg/mL) was 
used. The reaction was stopped after 50 minutes as this time point was found to be 
within the linear range in the previous experiment. Samples were then centrifuged, and 
the metabolite quantified by injecting the supernatants in LC-MS/MS. 
 After determining the optimal incubation times and HLM concentrations, an 
experiment to generate Michaelis-Menten plot was performed to find the Km and Vmax 
values of our system and ensure that the substrate concentration we use for the main 
experiments is below Km to prevent system saturation. A range of S-warfarin 
concentrations (0.5 – 64 uM) was incubated with 0.4 mg/mL HLM for 45 and 60 minutes 
(HLM concentration and incubation times were determined suitable by protein and time 
linearity experiments). The reaction was carried out in 100 mM Phosphate buffer as 
described earlier. 
2.4 Measurement of S-Warfarin Depletion and S-7-Hydroxywarfarin Formation 
 After finalizing the protocol with the optimal experimental settings, the main 
experiments were commenced using HLM samples from the individual donors. Each 
HLM sample (n=95) was incubated in a separate well in the 96-well plate. The incubation 
mixture consisted of 0.4 mg/mL HLM, 8 uM S-warfarin, 100 mM Phosphate buffer, and 
1.3 mM NADPH (total volume=180 uL). The mixture was preincubated in a water bath 
set at 37 ᴼC for 5 minutes prior to adding NADPH. Following preincubation, the 




to a quenching plate containing 80 uL quenching solution (2 uM S-7-hydroxywarfarin-d5 
as internal standard in ice cold acetonitrile) to measure the substrate at time zero. Four 
more 20 uL aliquots were taken at 12.5, 25, 37.5, and 50 minutes and added to the 
quenching plate. The quenching plate was then centrifuged, and the resulting 
supernatants were injected into LC-MS/MS. 
 Two calibration curves were created using known concentrations of S-warfarin 
(curve 1) and S-7OH-warfarin (curve 2) to interpolate concentrations of unknowns using 
linear regression. The remaining concentration of S-warfarin at different time points was 
used to measure its depletion and calculate the intrinsic clearance. The final aliquot at 
50 minutes was used to measure S-7OH-warfarin formation to determine CYP2C9 
activity. 
2.5 Quantification of S-Warfarin and S-7-Hydroxywarfarin 
 The LC-MS/MS instrument consisted of ACQUITY UPLC System equipped with a 
Vanguard pre-column, an ACQUITY UPLC BEH C18 column, and an autosampler. 
Attached to the UPLC system is an API 3200™ Triple Quad mass spectrometer with an 
electrospray ionization probe set at positive ion mode.  
 Chromatographic separation using a gradient elution mode was performed. 
Target column temperature was 50 ᴼC. The mobile phase constituted of 10 mM 
ammonium acetate with 5% acetonitrile at pH 4.85 (A) and 100% acetonitrile (B). The 




follows: A:B 95:5 (v/v) until 1 minute; A:B 75:25 (v/v) until 2.5 minutes; A:B 30:70 (v/v) 
until 3 minutes; A:B 10:90 (v/v) until 4 minutes; A:B 95:5 (v/v) until 5 minutes. 
2.6 Intrinsic Clearance Calculation 
 As indicated earlier, S-warfarin’s depletion over incubation time was used to 
calculate its intrinsic clearance in HLM samples. This method, known as in vitro t ½ 
approach, was performed as described by Obach et al. (1997). Briefly, resulting peak 
heights of the remaining substrate and the internal standard were recorded for each 
sample to calculate substrate peak height/IS peak height ratios. After that, the ratios 
were transformed to percentages using the ratio at time zero as %100 and then 
transformed again to the logarithmic form. The resulting values were plotted against 
their respective incubation times and slopes were calculated by doing linear regression 
analysis. Finally, the following formulas were utilized to calculate the intrinsic clearance 
(adapted from Obach, 1998): 
 slope = - k 




 CLint = 
0.693 x 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) x 45 𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠 x 20 𝑔 𝑙𝑖𝑣𝑒𝑟







2.7 Statistical analysis 
 Statistical analysis was performed using IBM SPSS Statistics version 24.0 for 
Windows (Released 2016. Armonk, NY: IBM Corp.). Normality was assessed using 
Shapiro-Wilk's test. Depending on normality results, one-way ANOVA or Kruskal-Wallis H 
test was chosen for testing the differences between more than two groups. The level of 
significance was set to be < 0.05. Calculation of Km and Vmax values and generation of 
graphs was done utilizing GraphPad Prism version 7.00 for Windows (GraphPad 







3.1 Preliminary Experiments 
 LC-MS/MS system linearity was observed for injected concentrations versus 
responses up until the highest concentration used for both S-warfarin and S-7OH-
warfarin (figures 1A and 1B respectively). 
 
Figure 1. LC-MS/MS system linearity for injected analyte concentration versus detected 
response. A. S-warfarin B. S-7OH-warfarin 
  
 S-7OH-warfarin formation was within the linear range for incubation times 
between 20 and 60 minutes (figure 2A) and HLM concentrations between 0.1 mg/mL 






Figure 2. Range of linearity of S-7OH-warfarin formation with respect to A. incubation 
time B. microsomal concentration 
 
 Two Michaelis-Menten plots were generated (figure 4). Vmax was 6.188 
picomole/min/mg HLM and 11.12 picomole/min/mg HLM after 45 and 60 minutes of 
















3.2 Effects of Diabetes and NAFLD on S-warfarin Intrinsic Clearance 
 Intrinsic clearance of S-warfarin per liver sample are shown in table 4. The 
distribution of CLint values did not differ significantly when compared between groups 
of different diabetic and NAFLD status (Table 5). 
3.3 Effects of Diabetes and NAFLD on CYP2C8 and 2C9 Expression and Activity 
 CYP2C9 activity did not seem to be significantly affected by either diabetes nor 
NAFLD status (Table 6). CYP2C8 mRNA and protein expression in addition to CYP2C9 
mRNA expression showed similar results of non-significant effect (Tables 7 and 8). 
Interestingly, however, CYP2C9 protein expression was significantly different between 







Figure 4. Boxplots representing the distribution of CYP2C9 protein levels across NAFLD 










                         Table 4. Intrinsic clearance (mL/min/kg) values for individual liver samples  
Liver ID CLint Liver ID CLint Liver ID CLint Liver ID CLint Liver ID CLint 
412 0.0000718 490 0.0000550 540 0.0000145 743 0.0000118 815 0.0000219 
415 0.0000595 493 0.0000804 542 0.0000056 749 0.0000419 816 0.0000145 
425 0.0000280 495 0.0000147 543 0.0000215 750 0.0000079 818 0.0000148 
447 0.0000009 498 0.0000229 545 0.0000350 752 0.0000031 821 0.0001027 
448 0.0000532 502 0.0000012 546 0.0000015 762 0.0000202 847 0.0000004 
450 0.0000580 508 0.0000223 548 0.0000011 768 0.0000361 850 0.0000035 
461 0.0000727 510 0.0000094 715 0.0000451 772 0.0000098 879 0.0000255 
465 0.0000984 527 0.0000027 717 0.0000206 791 0.0000842 892 0.0000192 
466 0.0000343 531 0.0000094 723 0.0000315 799 0.0000758 944 0.0000527 
467 0.0000065 533 0.0000131 740 0.0000825 802 0.0000537 981 0.0000014 







                      Table 5. Effect of diabetes and NAFLD on S-warfarin’s intrinsic clearance 






  p-values reported from data analysis using Kruskal-Wallis Test   ᵅ all mean and SD values are multiplied by 105 for  
  simplification  (for example: 4.3 is actually 0.000043)  










     
 
 
     
















  p-values reported from data analysis using Kruskal-Wallis Test 
  









     
 
 

















  p-values reported from data analysis using Kruskal-Wallis Test 
  
    Non-diabetic/no NAFLD (n=21)        Diabetic only (n=21)         NAFLD only (n=32)       Diabetic + NAFLD (n=32) 
CYP2C8 
mRNA 




    






















     Table 8. Effect of diabetes and NAFLD on CYP2C8 and CYP2C9 protein expression 










   
  p-values reported from data analysis using Kruskal-Wallis Test, * significant result  









    
  
         
 















                
 








 Pairwise comparisons using the Dunn-Bonferroni approach was performed as 
post hoc analysis to determine which groups showed the significant difference found in 
CYP2C9 protein expression (Table 9). Both the Diabetic only/ NAFLD only and Diabetic 
only/ Diabetic + NAFLD  pairwise comparisons were significant. Other comparisons were 
not significant. 
Table 9. Pairwise comparisons of CYP2C9 protein levels distribution between disease 
groups 
Pair p-value 
Diabetic + NAFLD/ NAFLD only 0.864 
Diabetic + NAFLD/ Normal 0.100 
Diabetic + NAFLD/ Diabetic only 0.019* 
NAFLD only/ Normal 0.130 
NAFLD only/ Diabetic only 0.026* 
Normal/ Diabetic only 0.534 
* significant result 
 
 To determine the magnitude of CYP2C9 protein level variability that is accounted 
by demographical data, multiple linear regression analysis was done. Age, gender, 
ethnicity, obesity, CYP2C9 polymorphism, diabetes/NAFLD status in addition to 
presence of phenytoin (CYP2C9 inducer) were all included as predictors in building the 
following regression model: 
CYP2C9 protein level (pmol/mg HLM) = 59.436 - 0.077 (age) + 17.385 (gender) - 5.903 
(ethnicity) + 6.14 (BMI) - 4.869 (polymorphism) - 7.058 (diabetes/NAFLD status) - 6.872 
(phenytoin) 
 The regression model was significant (p-value: 0.015) which indicates that at 




analyzing each predictor, gender and diabetic/NAFLD status were the only significant 
predictors (p-values: 0.007 and 0.018 respectively). A newer model was created 
incorporating only these predictors: 
CYP2C9 protein level (pmol/mg HLM) = 5.923 + 15.141 (gender) – 6.674 (diabetes/ 
NAFLD status) 
The adjusted R-square value is 0.111. In other words, 11.1% of the variability in CYP2C9 
protein expression can be explained by gender, diabetes, and NAFLD effects. 
 Multiple linear regression analysis was also performed to determine if any of the 
predictors mentioned above contribute to the variability in CYP2C8 mRNA, CYP2C8 
protein, and CYP2C9 mRNA expression. Presence of phenytoin was the only significant 
predictor of CYP2C8 mRNA level (p-value = 0.001). Age and diabetic/NAFLD status were 
predictors of CYP2C8 expression (p-values: 0.035 and 0.046 respectively). As for CYP2C9 
mRNA expression, presence of phenytoin and diabetic/NAFLD status were significant 
predictors (p-values: 0.01 and 0.026 respectively). 
 Although tetrahydrocannabinol (CYP2C9 inhibitor) was present in most of the 
livers. There was no notable influence of its presence on CYP2C9 activity and S-warfarin 
intrinsic clearance measured in HLM. This is not surprising when considering the process 
involved in hepatic microsomal preparation which is expected to remove much of the 





Discussion and Conclusions 
 Our findings have shown that CYP2C8’s mRNA and protein expression were not 
altered under the influence of two disease states: diabetes mellitus and NAFLD. 
Similarly, CYP2C9’s mRNA expression, activity levels, and S-warfarin’s intrinsic clearance 
showed no change. However, CYP2C9 protein levels significantly decreased in the 
NAFLD group and the combined diabetic and NAFLD group as compared to the diabetic 
only group. Multiple linear regression analysis showed that both diseases in addition to 
gender can explain about 11% of CYP2C9 protein level variability. 
 Several mechanisms have been proposed for the effect of diseases on hepatic 
drug metabolizing enzymes expression. Both diabetes mellitus (Sada et al., 2016; 
Norouzirad, Gonzalez-Muniesa, & Ghasemi, 2017) and NAFLD (Suzuki, Shinjo, Arai, 
Kanai, & Goda, 2014) are associated with a state of hypoxia. As reported by Simms & 
D'Amico (1996), there is a notable increased expression of cytokine receptors on cell 
surfaces in low oxygen states facilitating the intracellular effects of cytokines. Cytokines 
of interest to drug metabolism include Interleukin-1β and Interferon-γ which activate 
multiple intracellular signaling pathways that can eventually phosphorylate amino acid 
residues of some CYPs altering their activities (Fradette & Du Souich, 2004). 
Furthermore, these cytokines can activate intracellular cascades that lead to 
transcriptional modifications of CYP genes in the nucleus causing changes in protein 




suggested as a post-transcriptional down-regulator of some CYPs (du Souich & Fradette, 
2011). Apart from hypoxia, other conditions such as inflammation also play a role in 
CYPs alterations. Interleukin-6, which is a cytokine released in inflammation, was found 
to decrease mRNA levels of the nuclear receptors Constitutive Androstane Receptor 
(CAR) and Pregnane X Receptor (PXR). Both of which are crucial for induction of CYP2 
family genes (Pascussi et al., 2000). 
 There are some limitations to this study. The limited samples’ quantities 
prevented intrinsic clearance measurement using the metabolite formation approach 
which is a better-defined method than the in vitro half-life approach (Jones & Houston, 
2004). Additionally, the lack of information on how long the enzyme inducers were 
taken may cause inaccuracies. This is due to the possibility that some liver donors took 
an inducer for a period long enough to exert its effect on enzyme levels while others 
were exposed to an inducer for a short period before death. Furthermore, the low 
representation of different ethnicities and people with polymorphic forms of CYP2C8 
and CYP2C9 hinders the generalization of our findings. Finally, the nature of in vitro 
studies does not allow for direct clinical predictions as multiple factors in vivo can play a 
role in drug’s clearance such as liver blood flow and plasma protein binding. 
 In conclusion, this study provides some insight into CYP2C8 and CYP2C9 
expression and function in diabetic and/or NAFLD populations. Future studies in vivo are 





Ahmad, M., Iqbal, M., & Murtaza, G. (2012). Comparison of bioavailability and 
pharmacokinetics of diclofenac sodium and diclofenac potassium in normal and alloxan-
diabetic rabbits. Pakistan Journal of Pharmaceutical Sciences, 25(2), 301-306.  
Akhlaghi, F., Dostalek, M., Falck, P., Mendonza, A. E., Amundsen, R., Gohh, R. Y., & Åsberg, A. 
(2012). The concentration of cyclosporine metabolites is significantly lower in kidney 
transplant recipients with diabetes mellitus. Therapeutic Drug Monitoring, 34(1), 38-45. 
Antunes Nde, J., Cavalli, R. C., Marques, M. P., Moises, E. C., & Lanchote, V. L. (2015). Influence 
of gestational diabetes on the stereoselective pharmacokinetics and placental 
distribution of metoprolol and its metabolites in parturients. British Journal of Clinical 
Pharmacology, 79(4), 605-616. 
Atif M., A. M., uz-zaman QM., Asif M., Syed Sulaiman SA., Shafie AA., I Masood, Minhas U. and 
Us-saqib N. (2011). Glipizide Pharmacokinetics in Healthy and Diabetic Volunteers. 
Tropical Journal of Pharmaceutical Research, 10(2), 147-152.  
Babalik, A., Ulus, I. H., Bakirci, N., Kuyucu, T., Arpag, H., Dagyildizi, L., & Capaner, E. (2013). 
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary 
tuberculosis patients with diabetes mellitus. Antimicrobial Agents and Chemotherapy, 
57(11), 5740-5742. 
Backman, J. T., Filppula, A. M., Niemi, M., & Neuvonen, P. J. (2016). Role of Cytochrome P450 




Baldwin, S. J., Clarke, S. E., & Chenery, R. J. (1999). Characterization of the cytochrome P450 
enzymes involved in the in vitro metabolism of rosiglitazone. British Journal of Clinical 
Pharmacology, 48(3), 424-432.  
Bidstrup, T. B., Bjornsdottir, I., Sidelmann, U. G., Thomsen, M. S., & Hansen, K. T. (2003). 
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro 
biotransformation of the insulin secretagogue repaglinide. British Journal of Clinical 
Pharmacology, 56(3), 305-314.  
Bienert, A., Kaminska, A., Olszewski, J., Gracz, J., Grabowski, T., Wolc, A., & Grzeskowiak, E. 
(2012). Pharmacokinetics and ocular disposition of paracetamol and paracetamol 
glucuronide in rabbits with diabetes mellitus induced by alloxan. Pharmacoligical 
Reports, 64(2), 421-427.  
Brooks, H. B., Geeganage, S., Kahl, S. D., Montrose, C., Sittampalam, S., Smith, M. C., & 
Weidner, J. R. (2004). Basics of Enzymatic Assays for HTS. In G. S. Sittampalam, N. P. 
Coussens, K. Brimacombe, A. Grossman, M. Arkin, D. Auld, C. Austin, J. Baell, B. Bejcek, J. 
M. M. Caaveiro, T. D. Y. Chung, J. L. Dahlin, V. Devanaryan, T. L. Foley, M. Glicksman, M. 
D. Hall, J. V. Haas, J. Inglese, P. W. Iversen, S. D. Kahl, S. C. Kales, M. Lal-Nag, Z. Li, J. 
McGee, O. McManus, T. Riss, O. J. Trask, Jr., J. R. Weidner, M. J. Wildey, M. Xia, & X. Xu 
(Eds.), Assay Guidance Manual. Bethesda (MD). 
Bystrom, J., Wray, J. A., Sugden, M. C., Holness, M. J., Swales, K. E., Warner, T. D., Edin, M. L., 
Zeldin, D. C., Gilroy, D. W., Bishop-Bailey, D. (2011). Endogenous epoxygenases are 




Cao, Y., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2012). Pharmacokinetics of salsalate and 
salicylic acid in normal and diabetic rats. Biopharmaceutics & Drug Disposition, 33(6), 
285-291. 
Cederbaum, A. I. (2015). Molecular mechanisms of the microsomal mixed function oxidases and 
biological and pathological implications. Redox Biology, 4, 60-73. 
Chadha, G. S., & Morris, M. E. (2015). Effect of Type 2 Diabetes Mellitus and Diabetic 
Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. The 
American Association of Pharmaceutical Scientists Journal, 17(4), 965-975. 
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., Sanyal, 
A. J. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice 
Guideline by the American Association for the Study of Liver Diseases, American College 
of Gastroenterology, and the American Gastroenterological Association. Hepatology, 
55(6), 2005-2023. 
Chitnis, S. D., Ogasawara, K., Schniedewind, B., Gohh, R. Y., Christians, U., & Akhlaghi, F. (2013). 
Concentration of tacrolimus and major metabolites in kidney transplant recipients as a 
function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica, 
43(7), 641-649. 
Choonara, I. A., Haynes, B. P., Cholerton, S., Breckenridge, A. M., & Park, B. K. (1986). 
Enantiomers of warfarin and vitamin K1 metabolism. British Journal of Clinical 




Cooper, D. Y., Schleyer, H., Levin, S. S., Eisenhardt, R. H., Novack, B. G., & Rosenthal, O. (1979). 
A reevaluation of the role of cytochrome P-450 as the terminal oxidase in hepatic 
microsomal mixed function oxidase catalyzed reactions. Drug Metabolism Reviews, 
10(2), 153-185. 
COUMADIN Prescribing information. (2011).   Retrieved from 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf. 
Accessed February 2018. 
de Moraes, N. V., Lauretti, G. R., & Lanchote, V. L. (2014). Effects of type 1 and type 2 diabetes 
on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain 
phenotyped as cytochrome P450 2D6 extensive metabolizers. Journal of Pharmacy and 
Pharmacology, 66(9), 1222-1230. 
Dhande, S. R., Lokegaonkar, D. V., & Bhutkar, S. P. (2017). Effect of Gymnema Sylvestre on the 
pharmacokinetics of sitagliptin phosphate in type II diabetes mellitus. International 
Journal of Pharmaceutical Sciences and Research, 8(3), 1160-1167. 
Dostalek, M., Akhlaghi, F., & Puzanovova, M. (2012). Effect of diabetes mellitus on 
pharmacokinetic and pharmacodynamic properties of drugs. Clinical Pharmacokinetics, 
51(8), 481-499. 
Dostalek, M., Court, M. H., Yan, B., & Akhlaghi, F. (2011). Significantly reduced cytochrome P450 
3A4 expression and activity in liver from humans with diabetes mellitus. British Journal 





du Souich, P., & Fradette, C. (2011). The effect and clinical consequences of hypoxia on 
cytochrome P450, membrane carrier proteins activity and expression. Expert Opinion on 
Drug Metabolism & Toxicology, 7(9), 1083-1100. 
Filgueira, G. C. D. O., Filgueira, O. A. S., Carvalho, D. M., Marques, M. P., Moisés, E. C. D., 
Duarte, G., Lanchote, V. L., Cavalli, R. C. (2017). Effect of type 2 diabetes mellitus on the 
pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant 
women. British Journal of Clinical Pharmacology, 83(7), 1571-1579. 
Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., & 
Cherrington, N. J. (2009). Hepatic cytochrome P450 enzyme alterations in humans with 
progressive stages of nonalcoholic fatty liver disease. Drug Metabolism and Disposition, 
37(10), 2087-2094. 
Flora, D. R., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2017). CYP2C9 Genotype-Dependent 
Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their 
Oxidative Metabolites. The Journal of Clinical Pharmacology, 57(3), 382-393. 
Fradette, C., & Du Souich, P. (2004). Effect of hypoxia on cytochrome P450 activity and 
expression. Current Drug Metabolism, 5(3), 257-271. 
Furge, L. L., & Guengerich, F. P. (2006). Cytochrome P450 enzymes in drug metabolism and 





Goldstein, J. A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C 
subfamily. British Journal of Clinical Pharmacology, 52(4), 349-355. 
Hodgson, E. (1979). Comparative aspects of the distribution of cytochrome P-450 dependent 
mono-oxygenase systems: an overview. Drug Metabolism Reviews, 10(1), 15-33. 
Hu, N., Hu, M., Duan, R., Liu, C., Guo, H., Zhang, M., Yu, Y., Wang, X., Liu, L., Liu, X. (2014). 
Increased levels of fatty acids contributed to induction of hepatic CYP3A4 activity 
induced by diabetes - in vitro evidence from HepG2 cell and Fa2N-4 cell lines. Journal Of 
Pharmacological Sciences, 124(4), 433-444.  
Ionita, I. A., Ogasawara, K., Gohh, R. Y., & Akhlaghi, F. (2014). Pharmacokinetics of total and 
unbound prednisone and prednisolone in stable kidney transplant recipients with 
diabetes mellitus. Therapeutic Drug Monitoring, 36(4), 448-455. 
Jaakkola, T., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2006). Pioglitazone is metabolised by 
CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic & 
Clinical Pharmacology & Toxicology, 99(1), 44-51. 
Jamwal, R., Barlock, B. J., Adusumalli, S., Ogasawara, K., Simons, B. L., & Akhlaghi, F. (2017). 
Multiplex and Label-Free Relative Quantification Approach for Studying Protein 
Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-
MS. Journal of Proteome Research, 16(11), 4134-4143. 
Jamwal, R., de la Monte, S. M., Ogasawara, K., Adusumalli, S., Barlock, B. B., & Akhlaghi, F. 




CYP3A4 Protein Expression and Activity in Human Liver. Molecular Pharmaceutics, 15(7), 
2621-2632. 
Jones, H. M., & Houston, J. B. (2004). Substrate depletion approach for determining in vitro 
metabolic clearance: time dependencies in hepatocyte and microsomal incubations. 
Drug Metabolism and Disposition, 32(9), 973-982. 
Ju, W., Peng, K., Yang, S., Sun, H., Sampson, M., & Wang, M. Z. (2014). A chiral HPLC-MS/MS 
method for simultaneous quantification of warfarin enantiomers and its major 
hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma. Austin journal of 
analytical and pharmaceutical chemistry, 1(2). 
Kapur, A., O'Connor-Semmes, R., Hussey, E. K., Dobbins, R. L., Tao, W., Hompesch, M., Smith, G. 
A., Polli, J. W., James Jr, C. D., Mikoshiba, I., Nunez, D. J. (2013). First human dose-
escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-
glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes 
mellitus. BMC Pharmacology and Toxicology, 14, 26. 
Karaźniewicz‑Łada, M., Danielak, D., Burchardt, P., & Główka, F. (2014). The influence of 
diabetic status on the pharmacokinetics of clopidogrel and its metabolites in patients 
suffered from cardiovascular diseases. Journal of Medical Science, 83(3), 7.  
Karbownik, A., Szałek, E., Sobańska, K., Klupczynska, A., Plewa, S., Grabowski, T., Wolc, A., 
Moch, M., Kokot, Z. J., Grześkowiak, E. (2018). A pharmacokinetic study on lapatinib in 




Kohl, C., & Steinkellner, M. (2000). Prediction of pharmacokinetic drug/drug interactions from 
In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with 
oral anticoagulants. Drug Metabolism and Disposition, 28(2), 161-168.  
Kroetz, D. L., & Zeldin, D. C. (2002). Cytochrome P450 pathways of arachidonic acid metabolism. 
Current Opinion In Lipidology, 13(3), 273-283. 
Laerd Statistics (2015). Kruskal-Wallis H test using SPSS Statistics. Statistical tutorials and 
software guides. Retrieved from https://statistics.laerd.com/. Accessed March 2018. 
Laerd Statistics (2015). Mann-Whitney U test using SPSS Statistics. Statistical tutorials and 
software guides. Retrieved from https://statistics.laerd.com/. Accessed March 2018. 
Laerd Statistics (2015). Statistical tutorials and software guides. Retrieved from 
https://statistics.laerd.com/. Accessed March 2018. 
Lee, D. Y., Lee, M. G., Shin, H. S., & Lee, I. (2007). Changes in omeprazole pharmacokinetics in 
rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole 
due to induction of hepatic CYP1A2 and 3A1. Journal of Pharmacy and Pharmaceutical 
Sciences, 10(4), 420-433.  
Lee, J. H., Lee, A., Oh, J. H., & Lee, Y. J. (2012). Comparative pharmacokinetic study of paclitaxel 
and docetaxel in streptozotocin-induced diabetic rats. Biopharmaceutics & Drug 




Li, H., Canet, M. J., Clarke, J. D., Billheimer, D., Xanthakos, S. A., Lavine, J. E., Erickson, R. P., 
Cherrington, N. J. (2017). Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic 
Steatohepatitis. Drug Metabolism and Disposition, 45(12), 1317-1325. 
Li, H., Clarke, J. D., Dzierlenga, A. L., Bear, J., Goedken, M. J., & Cherrington, N. J. (2017). In vivo 
cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. 
Journal of Biochemical and Molecular Toxicology, 31(2). 
Li, S. S., Song, Z. H., Xiong, L. Q., Zhang, Q., Liu, Q., & Li, G. F. (2014). The percutaneous 
permeability and absorption of dexamethasone esters in diabetic rats: a preliminary 
study. Drug Delivery, 21(1), 17-25. 
Li, Y., Wei, Y., Zhang, F., Wang, D., & Wu, X. (2012). Changes in the pharmacokinetics of 
glibenclamide in rats with streptozotocin-induced diabetes mellitus. Acta Pharmaceutica 
Sinica B, 2(2), 196-202. 
Lucas, D., Farez, C., Bardou, L. G., Vaisse, J., Attali, J. R., & Valensi, P. (1998). Cytochrome P450 
2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. 
Fundamental & Clinical Pharmacology, 12(5), 553-558.  
Medellin-Garibay, S. E., Cortez-Espinosa, N., Milan-Segovia, R. C., Magana-Aquino, M., Vargas-
Morales, J. M., Gonzalez-Amaro, R., Portales-Perez, D. P., Romano-Moreno, S. (2015). 
Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes 
Mellitus: Association with Biochemical and Immunological Parameters. Antimicrobial 




Naraharisetti, S. B., Lin, Y. S., Rieder, M. J., Marciante, K. D., Psaty, B. M., Thummel, K. E., & 
Totah, R. A. (2010). Human liver expression of CYP2C8: gender, age, and genotype 
effects. Drug Metabolism and Disposition, 38(6), 889-893. 
Nath, A., & Atkins, W. M. (2006). A theoretical validation of the substrate depletion approach to 
determining kinetic parameters. Drug Metabolism and Disposition, 34(9), 1433-1435. 
Niijima, S., Ohmori, T., & Kario, K. (2018). Differential impact of diabetes mellitus on antiplatelet 
effects of prasugrel and clopidogrel. Thrombosis Journal, 16, 5. 
Norouzirad, R., Gonzalez-Muniesa, P., & Ghasemi, A. (2017). Hypoxia in Obesity and Diabetes: 
Potential Therapeutic Effects of Hyperoxia and Nitrate. Oxidative Medicine and Cellular 
Longevity, 2017, 5350267. 
Obach, R. S. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic 
clearance to hepatic clearance as assessed through examination of warfarin, 
imipramine, and propranolol. Drug Metabolism and Disposition, 25(12), 1359-1369.  
Obach, R. S. (1999). Prediction of human clearance of twenty-nine drugs from hepatic 
microsomal intrinsic clearance data: An examination of in vitro half-life approach and 
nonspecific binding to microsomes. Drug Metabolism and Disposition, 27(11), 1350-
1359.  
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., MacIntyre, F., Rance, D. J., 




preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental 
Therapeutics, 283(1), 46-58.  
Obach, R. S., & Reed-Hagen, A. E. (2002). Measurement of Michaelis constants for cytochrome 
P450-mediated biotransformation reactions using a substrate depletion approach. Drug 
Metabolism and Disposition, 30(7), 831-837. 
Pardo Campos Godoy, A. L., Martinez, E. Z., Marques, M. P., de Carvalho Leone, A., Barbosa 
Coelho, E., & Lucia Lanchote, V. (2014). Influence of experimental diabetes and insulin 
treatment on the enantioselective pharmacokinetics of mexiletine and its metabolites. 
Canadian Journal of Physiology and Pharmacology, 92(3), 263-266. 
Park, B. K. (1988). Warfarin: metabolism and mode of action. Biochemical Pharmacology, 37(1), 
19-27. 
Pascussi, J. M., Gerbal-Chaloin, S., Pichard-Garcia, L., Daujat, M., Fabre, J. M., Maurel, P., & 
Vilarem, M. J. (2000). Interleukin-6 negatively regulates the expression of pregnane X 
receptor and constitutively activated receptor in primary human hepatocytes. 
Biochemical and Biophysical Research Communications, 274(3), 707-713. 
Patoine, D., Petit, M., Pilote, S., Picard, F., Drolet, B., & Simard, C. (2014). Modulation of CYP3a 
expression and activity in mice models of type 1 and type 2 diabetes. Pharmacology 




Penta, J., Gorre, T., & Yellu, N. R. (2017). Pharmacokinetic and pharmacodynamic interaction 
study of curcumin with repaglinide in normal and diabetic rats. Journal of Global Trends 
in Pharmaceutical Sciences, 8(3), 4130-4137.  
Requena-Mendez, A., Davies, G., Waterhouse, D., Ardrey, A., Jave, O., Lopez-Romero, S. L., 
Ward, S. A., Moore, D. A. (2014). Effects of dosage, comorbidities, and food on isoniazid 
pharmacokinetics in Peruvian tuberculosis patients. Antimicrobial Agents and 
Chemotherapy, 58(12), 7164-7170. 
Rettie, A. E., Eddy, A. C., Heimark, L. D., Gibaldi, M., & Trager, W. F. (1989). Characteristics of 
warfarin hydroxylation catalyzed by human liver microsomes. Drug Metabolism and 
Disposition, 17(3), 265-270. 
Rifkind, A. B., Lee, C., Chang, T. K., & Waxman, D. J. (1995). Arachidonic acid metabolism by 
human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and 
evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver 
microsomes. Archives of Biochemistry and Biophysics, 320(2), 380-389. 
Ruikar, D. B., & Rajput, S. J. (2012). Optimization of the in vitro oxidative biotransformation of 
glimepiride as a model substrate for cytochrome p450 using factorial design. DARU 
Journal of Pharmaceutical Sciences, 20(1), 38. 
Sada, K., Nishikawa, T., Kukidome, D., Yoshinaga, T., Kajihara, N., Sonoda, K., Senokuchi, T., 
Motoshima, H., Matsumura, T. Araki, E. (2016). Hyperglycemia Induces Cellular Hypoxia 
through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. PLoS 




Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. 
L. (2017). The Effect of Renal Impairment on the Pharmacokinetics and 
Pharmacodynamics of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus. The 
Journal of Clinical Pharmacology, 57(11), 1432-1443. 
Samala, S., & Veeresham, C. (2016). Pharmacokinetic and Pharmacodynamic Interaction of 
Boswellic Acids and Andrographolide with Glyburide in Diabetic Rats: Including Its PK/PD 
Modeling. Phytotherapy Research, 30(3), 496-502. 
Sane, R., & Sinz, M. (2017). Chapter 1 - Introduction of Drug Metabolism and Overview of 
Disease Effect on Drug Metabolism A2 - Xie, Wen. Drug Metabolism in Diseases (pp. 1-
19). Boston: Academic Press. 
Sapmaz, F., Kalkan, I. H., Suslu, I., Demirci, H., Atasoy, P., & Guliter, S. (2015). Lower plasma 
pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 
diabetes mellitus. Journal of Digestive Diseases, 16(9), 531-536. 
Simms, H., & D'Amico, R. (1996). Regulation of polymorphonuclear leukocyte cytokine receptor 
expression: the role of altered oxygen tensions and matrix proteins. The Journal of 
Immunology, 157(8), 3605-3616. 
Singh, J., & Patel, S. C. (2013). Pharmacokinetic changes of fluvoxamine and pioglitazone by 
drug drug interaction in healthy, diabetic and depressive rats. International Journal of 




Spector, A. A., Fang, X., Snyder, G. D., & Weintraub, N. L. (2004). Epoxyeicosatrienoic acids 
(EETs): metabolism and biochemical function. Progress in Lipid Research, 43(1), 55-90. 
Stainton, S. M., Monogue, M. L., Baummer-Carr, A., Shepard, A. K., Nugent, J. F., Kuti, J. L., & 
Nicolau, D. P. (2018). Comparative Assessment of Tedizolid Pharmacokinetics and Tissue 
Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers 
via In Vivo Microdialysis. Antimicrobial Agents and Chemotherapy, 62(1). 
Suzuki, T., Shinjo, S., Arai, T., Kanai, M., & Goda, N. (2014). Hypoxia and fatty liver. World 
Journal of Gastroenterology, 20(41), 15087-15097. 
Szalek, E., Karbownik, A., Sobanska, K., Grabowski, T., Polom, W., Lewandowska, M., Wolc, A., 
Matuszewski, M., Grzeskowiak, E. (2014). The pharmacokinetics and hypoglycaemic 
effect of sunitinib in the diabetic rabbits. Pharmacological Reports, 66(5), 892-896. 
Van Booven, D., Marsh, S., McLeod, H., Carrillo, M. W., Sangkuhl, K., Klein, T. E., & Altman, R. B. 
(2010). Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and Genomics, 20(4), 277-
281. 
Veeresham, C., Sujatha, S., & Rani, T. S. (2012). Effect of piperine on the pharmacokinetics and 
pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats. 
Natural Product Communications, 7(10), 1283-1286.  
Vunnam, R. R., Sriharsha, S. N., & Rajesham, V. V. (2015). Pharmacokinetic drug interactions of 
Gliclazide and itopride in normal and diabetic rats. International Journal of Pharmacy 




Wang, Z., Hall, S. D., Maya, J. F., Li, L., Asghar, A., & Gorski, J. C. (2003). Diabetes mellitus 
increases the in vivo activity of cytochrome P450 2E1 in humans. British Journal of 
Clinical Pharmacology, 55(1), 77-85.  
World Health Organization. (2017). Diabetes.   Retrieved from 
http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed February 2018. 
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global 
epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of 
prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84. 
Zhou, X., Rougee, L. R., Bedwell, D. W., Cramer, J. W., Mohutsky, M. A., Calvert, N. A., Moulton, 
R. D., Cassidy, K. C., Yumibe, N. P., Adams, L. A., Ruterbories, K. J. (2016). Difference in 
the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic 
Fatty and Sprague-Dawley Rats. Drug Metabolism and Disposition, 44(8), 1184-1192. 
